Salvador Chulián
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Salvador Chulián has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Víctor Manuel Pérez García
University of Castile-La Mancha
12 shared publications - Maria Rosa
Department of Mathematics, Universidad de Cádiz, Puerto Real, Spain
11 shared publications - Álvaro Martínez-Rubio
Department of Mathematics, University of Cadiz, Puerto Real, Spain
10 shared publications Ana Castillo Robleda
Oncohematology Unit, Niño Jesús University Children’s Hospital, Madrid, Spain
6 shared publications- Manuel Ramírez
Department of Pediatric Hematology and Oncology, Niño Jesús University Hospital, Madrid, Madrid, Spain
6 shared publications María Rosa
Department of Mathematics, University of Cadiz, Puerto Real, Spain
6 shared publications
Latest Publications
- Open Access
Automatic computational classification of bone marrow cells for B cell pediatric leukemia using UMAP
B Acute Lymphoblastic Leukemia (B-ALL) accounts for approximately 80% of pediatric leukemia cases. Despite treatment advances, 15–20% of children experience relapse, highlighting the need of improved monitoring of patients and novel strategies leading to successful therapies. Flow Cytometry is an essential technique for measuring residual disease and guiding treatment. However, traditional manual gating limits its efficiency. In recent years, computational tools have been integrated to enhance these clinical processes but many mathematical techniques are underexploited. Particularly, Uniform Manifold Approximation and Projection (UMAP), together with Machine Learning, provide promising approaches for analyzing large datasets. Mathematical tools and artificial intelligence offer new perspectives on these health problems, beyond the usual approach in biomedicine. We have exploited 234 samples from 75 B-ALL patients to develop an artificial intelligence-based algorithm that can improve patient classification and therapy decisions in different patient cohorts. This implies an advancement on the routine manual analysis of the disease progression, as we identify key subpopulations automatically, distinguishing patients’ bone marrow regeneration patterns, thus improving the prediction and prognosis of the disease. MSC Classification: 68-04, 68T09, 90C90, 92B05 Abbreviations: A list of abbreviations used throughout this work can be found in Appendix A.
Open AccessAutomatic computational classification of bone marrow cells for B cell pediatric leukemia using UMAP
B Acute Lymphoblastic Leukemia (B-ALL) accounts for approximately 80% of pediatric leukemia cases. Despite treatment advances, 15–20% of children experience relapse, highlighting the need of improved monitoring of patients and novel strategies leading to successful therapies. Flow Cytometry is an essential technique for measuring residual disease and guiding treatment. However, traditional manual gating limits its efficiency. In recent years, computational tools have been integrated to enhance these clinical processes but many mathematical techniques are underexploited. Particularly, Uniform Manifold Approximation and Projection (UMAP), together with Machine Learning, provide promising approaches for analyzing large datasets. Mathematical tools and artificial intelligence offer new perspectives on these health problems, beyond the usual approach in biomedicine. We have exploited 234 samples from 75 B-ALL patients to develop an artificial intelligence-based algorithm that can improve patient classification and therapy decisions in different patient cohorts. This implies an advancement on the routine manual analysis of the disease progression, as we identify key subpopulations automatically, distinguishing patients’ bone marrow regeneration patterns, thus improving the prediction and prognosis of the disease. MSC Classification: 68-04, 68T09, 90C90, 92B05 Abbreviations: A list of abbreviations used throughout this work can be found in Appendix A.
- Open Access
- 20 February 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 188, 109831
Computational flow cytometry immunophenotyping at diagnosis is unable to predict relapse in childhood B-cell Acute Lymphoblastic Leukemia
- 20 February 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 188, 109831
Open AccessComputational flow cytometry immunophenotyping at diagnosis is unable to predict relapse in childhood B-cell Acute Lymphoblastic Leukemia
- Open Access
Computational flow cytometry immunophenotyping at diagnosis is unable to predict relapse in childhood B-cell Acute Lymphoblastic Leukemia
B-cell Acute Lymphoblastic Leukemia is the most prevalent form of childhood cancer, with approximately 15% of patients undergoing relapse after initial treatment. Further advancements depend on novel therapies and more precise risk stratification criteria. In the context of computational flow cytometry and machine learning, this paper aims to explore the potential prognostic value of flow cytometry data at diagnosis, a relatively unexplored direction for relapse prediction in this disease. To this end, we collected a dataset of 252 patients from three hospitals and implemented a comprehensive pipeline for multicenter data integration, feature extraction, and patient classification, comparing the results with existing algorithms from the literature. The analysis revealed no significant differences in immunophenotypic patterns between relapse and non-relapse patients and suggests the need for alternative approaches to handle flow cytometry data in relapse prediction.
Open AccessComputational flow cytometry immunophenotyping at diagnosis is unable to predict relapse in childhood B-cell Acute Lymphoblastic Leukemia
B-cell Acute Lymphoblastic Leukemia is the most prevalent form of childhood cancer, with approximately 15% of patients undergoing relapse after initial treatment. Further advancements depend on novel therapies and more precise risk stratification criteria. In the context of computational flow cytometry and machine learning, this paper aims to explore the potential prognostic value of flow cytometry data at diagnosis, a relatively unexplored direction for relapse prediction in this disease. To this end, we collected a dataset of 252 patients from three hospitals and implemented a comprehensive pipeline for multicenter data integration, feature extraction, and patient classification, comparing the results with existing algorithms from the literature. The analysis revealed no significant differences in immunophenotypic patterns between relapse and non-relapse patients and suggests the need for alternative approaches to handle flow cytometry data in relapse prediction.
- Open Access
- 20 November 2023
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 19 (11) , e1011208
Overcoming chemotherapy resistance in low-grade gliomas: A computational approach
Low-grade gliomas are primary brain tumors that arise from glial cells and are usually treated with temozolomide (TMZ) as a chemotherapeutic option. They are often incurable, but patients have a prolonged survival. One of the shortcomings of the treatment is that patients eventually develop drug resistance. Recent findings show that persisters, cells that enter a dormancy state to resist treatment, play an important role in the development of resistance to TMZ. In this study we constructed a mathematical model of low-grade glioma response to TMZ incorporating a persister population. The model was able to describe the volumetric longitudinal dynamics, observed in routine FLAIR 3D sequences, of low-grade glioma patients acquiring TMZ resistance. We used the model to explore different TMZ administration protocols, first on virtual clones of real patients and afterwards on virtual patients preserving the relationships between parameters of real patients. In silico clinical trials showed that resistance development was deferred by protocols in which individual doses are administered after rest periods, rather than the 28-days cycle standard protocol. This led to median survival gains in virtual patients of more than 15 months when using resting periods between two and three weeks and agreed with recent experimental observations in animal models. Additionally, we tested adaptive variations of these new protocols, what showed a potential reduction in toxicity, but no survival gain. Our computational results highlight the need of further clinical trials that could obtain better results from treatment with TMZ in low grade gliomas.
- 20 November 2023
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 19 (11) , e1011208
Open AccessOvercoming chemotherapy resistance in low-grade gliomas: A computational approach
Low-grade gliomas are primary brain tumors that arise from glial cells and are usually treated with temozolomide (TMZ) as a chemotherapeutic option. They are often incurable, but patients have a prolonged survival. One of the shortcomings of the treatment is that patients eventually develop drug resistance. Recent findings show that persisters, cells that enter a dormancy state to resist treatment, play an important role in the development of resistance to TMZ. In this study we constructed a mathematical model of low-grade glioma response to TMZ incorporating a persister population. The model was able to describe the volumetric longitudinal dynamics, observed in routine FLAIR 3D sequences, of low-grade glioma patients acquiring TMZ resistance. We used the model to explore different TMZ administration protocols, first on virtual clones of real patients and afterwards on virtual patients preserving the relationships between parameters of real patients. In silico clinical trials showed that resistance development was deferred by protocols in which individual doses are administered after rest periods, rather than the 28-days cycle standard protocol. This led to median survival gains in virtual patients of more than 15 months when using resting periods between two and three weeks and agreed with recent experimental observations in animal models. Additionally, we tested adaptive variations of these new protocols, what showed a potential reduction in toxicity, but no survival gain. Our computational results highlight the need of further clinical trials that could obtain better results from treatment with TMZ in low grade gliomas.
- Open Access
- 14 August 2023
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 19 (8) , e1011329
The shape of cancer relapse: Topological data analysis predicts recurrence in paediatric acute lymphoblastic leukaemia
Although children and adolescents with acute lymphoblastic leukaemia (ALL) have high survival rates, approximately 15-20% of patients relapse. Risk of relapse is routinely estimated at diagnosis by biological factors, including flow cytometry data. This high-dimensional data is typically manually assessed by projecting it onto a subset of biomarkers. Cell density and “empty spaces” in 2D projections of the data, i.e. regions devoid of cells, are then used for qualitative assessment. Here, we use topological data analysis (TDA), which quantifies shapes, including empty spaces, in data, to analyse pre-treatment ALL datasets with known patient outcomes. We combine these fully unsupervised analyses with Machine Learning (ML) to identify significant shape characteristics and demonstrate that they accurately predict risk of relapse, particularly for patients previously classified as ‘low risk’. We independently confirm the predictive power of CD10, CD20, CD38, and CD45 as biomarkers for ALL diagnosis. Based on our analyses, we propose three increasingly detailed prognostic pipelines for analysing flow cytometry data from ALL patients depending on technical and technological availability: 1. Visual inspection of specific biological features in biparametric projections of the data; 2. Computation of quantitative topological descriptors of such projections; 3. A combined analysis, using TDA and ML, in the four-parameter space defined by CD10, CD20, CD38 and CD45. Our analyses readily extend to other haematological malignancies.
- 14 August 2023
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 19 (8) , e1011329
Open AccessThe shape of cancer relapse: Topological data analysis predicts recurrence in paediatric acute lymphoblastic leukaemia
Although children and adolescents with acute lymphoblastic leukaemia (ALL) have high survival rates, approximately 15-20% of patients relapse. Risk of relapse is routinely estimated at diagnosis by biological factors, including flow cytometry data. This high-dimensional data is typically manually assessed by projecting it onto a subset of biomarkers. Cell density and “empty spaces” in 2D projections of the data, i.e. regions devoid of cells, are then used for qualitative assessment. Here, we use topological data analysis (TDA), which quantifies shapes, including empty spaces, in data, to analyse pre-treatment ALL datasets with known patient outcomes. We combine these fully unsupervised analyses with Machine Learning (ML) to identify significant shape characteristics and demonstrate that they accurately predict risk of relapse, particularly for patients previously classified as ‘low risk’. We independently confirm the predictive power of CD10, CD20, CD38, and CD45 as biomarkers for ALL diagnosis. Based on our analyses, we propose three increasingly detailed prognostic pipelines for analysing flow cytometry data from ALL patients depending on technical and technological availability: 1. Visual inspection of specific biological features in biparametric projections of the data; 2. Computation of quantitative topological descriptors of such projections; 3. A combined analysis, using TDA and ML, in the four-parameter space defined by CD10, CD20, CD38 and CD45. Our analyses readily extend to other haematological malignancies.
- Open Access
Breaking Down Cell-Free DNA Fragmentation: A Markov Model Approach
Cell-free DNA (cfDNA) is released into the bloodstream from cells in various physiological and pathological conditions. The use of cfDNA as a non-invasive biomarker has attracted attention, but the dynamics of cfDNA fragmentation in the bloodstream are not well understood and have not been previously studied computationally. To address this issue, we present a Markovian model called FRIME (Fragmentation, Immigration, and Exit) that captures three leading mechanisms governing cfDNA fragmentation in the bloodstream. The FRIME model enables the simulation of cfDNA fragment profiles by sampling from the stationary distribution of FRIME processes. By varying the parameters of our model, we generate fragment profiles similar to those observed in liquid biopsies and provide insight into the underlying biological mechanisms driving the fragmentation dynamics. To validate our model, we compare simulated FRIME profiles with mitochondrial and genomic cfDNA fragment profiles. Our simulation results are consistent with experimental and clinical observations and highlight potential physicochemical differences between mitochondrial and genomic cfDNA. The FRIME simulation framework provides an initial step towards an improved computational understanding of DNA fragmentation dynamics in the bloodstream and may aid in the analysis of liquid biopsy data. Author summary: Cell-free DNA (cfDNA) released into the bloodstream from cells in different conditions is the basis for liquid biopsies, thus being non-invasive biomarkers of potential interest. However, the dynamics of cfDNA fragmentation in the bloodstream remain poorly understood and are yet to be studied computationally. To address this issue, we developed a Markovian model which captures the three leading mechanisms governing cfDNA fragmentation in the bloodstream: FRagmentation, IMmigration, and Exit (FRIME). The FRIME model enables the simulation of cfDNA fragment profiles by sampling from the stationary distribution of FRIME processes. Simulation results are compared with mitochondrial and genomic cfDNA fragment profiles, which show consistency with experimental and clinical observations. The FRIME simulation framework is a significant step towards understanding DNA fragmentation dynamics in the bloodstream, uncovering potential physicochemical differences between mitochondrial and genomic cfDNA, and aiding the analysis of liquid biopsy data.
Open AccessBreaking Down Cell-Free DNA Fragmentation: A Markov Model Approach
Cell-free DNA (cfDNA) is released into the bloodstream from cells in various physiological and pathological conditions. The use of cfDNA as a non-invasive biomarker has attracted attention, but the dynamics of cfDNA fragmentation in the bloodstream are not well understood and have not been previously studied computationally. To address this issue, we present a Markovian model called FRIME (Fragmentation, Immigration, and Exit) that captures three leading mechanisms governing cfDNA fragmentation in the bloodstream. The FRIME model enables the simulation of cfDNA fragment profiles by sampling from the stationary distribution of FRIME processes. By varying the parameters of our model, we generate fragment profiles similar to those observed in liquid biopsies and provide insight into the underlying biological mechanisms driving the fragmentation dynamics. To validate our model, we compare simulated FRIME profiles with mitochondrial and genomic cfDNA fragment profiles. Our simulation results are consistent with experimental and clinical observations and highlight potential physicochemical differences between mitochondrial and genomic cfDNA. The FRIME simulation framework provides an initial step towards an improved computational understanding of DNA fragmentation dynamics in the bloodstream and may aid in the analysis of liquid biopsy data. Author summary: Cell-free DNA (cfDNA) released into the bloodstream from cells in different conditions is the basis for liquid biopsies, thus being non-invasive biomarkers of potential interest. However, the dynamics of cfDNA fragmentation in the bloodstream remain poorly understood and are yet to be studied computationally. To address this issue, we developed a Markovian model which captures the three leading mechanisms governing cfDNA fragmentation in the bloodstream: FRagmentation, IMmigration, and Exit (FRIME). The FRIME model enables the simulation of cfDNA fragment profiles by sampling from the stationary distribution of FRIME processes. Simulation results are compared with mitochondrial and genomic cfDNA fragment profiles, which show consistency with experimental and clinical observations. The FRIME simulation framework is a significant step towards understanding DNA fragmentation dynamics in the bloodstream, uncovering potential physicochemical differences between mitochondrial and genomic cfDNA, and aiding the analysis of liquid biopsy data.
- Open Access
- 29 July 2022
- Published by Springer Nature in SeMA Journal
- Vol. 79 (3) , 487-488
Correction to: Mathematical models of leukaemia and its treatment: a review
- 29 July 2022
- Published by Springer Nature in SeMA Journal
- Vol. 79 (3) , 487-488
Open AccessCorrection to: Mathematical models of leukaemia and its treatment: a review
- Open Access
- 3 May 2022
- Published by Springer Nature in SeMA Journal
- Vol. 79 (3) , 441-486
Mathematical models of leukaemia and its treatment: a review
Leukaemia accounts for around 3% of all cancer types diagnosed in adults, and is the most common type of cancer in children of paediatric age (typically ranging from 0 to 14 years). There is increasing interest in the use of mathematical models in oncology to draw inferences and make predictions, providing a complementary picture to experimental biomedical models. In this paper we recapitulate the state of the art of mathematical modelling of leukaemia growth dynamics, in time and response to treatment. We intend to describe the mathematical methodologies, the biological aspects taken into account in the modelling, and the conclusions of each study. This review is intended to provide researchers in the field with solid background material, in order to achieve further breakthroughs in the promising field of mathematical biology.
- 3 May 2022
- Published by Springer Nature in SeMA Journal
- Vol. 79 (3) , 441-486
Open AccessMathematical models of leukaemia and its treatment: a review
Leukaemia accounts for around 3% of all cancer types diagnosed in adults, and is the most common type of cancer in children of paediatric age (typically ranging from 0 to 14 years). There is increasing interest in the use of mathematical models in oncology to draw inferences and make predictions, providing a complementary picture to experimental biomedical models. In this paper we recapitulate the state of the art of mathematical modelling of leukaemia growth dynamics, in time and response to treatment. We intend to describe the mathematical methodologies, the biological aspects taken into account in the modelling, and the conclusions of each study. This review is intended to provide researchers in the field with solid background material, in order to achieve further breakthroughs in the promising field of mathematical biology.
- Open Access
The shape of cancer relapse: Topological data analysis predicts recurrence in paediatric acute lymphoblastic leukaemia
Although children and adolescents with acute lymphoblastic leukaemia (ALL) have high survival rates, approximately 15-20% of patients relapse. Risk of relapse is routinely estimated at diagnosis by biological factors, including flow cytometry data. This high-dimensional data is typically manually assessed by projecting it onto a subset of biomarkers. Cell density and “empty spaces” in 2D projections of the data, i.e. regions devoid of cells, are then used for qualitative assessment. Here, we use topological data analysis (TDA), which quantifies shapes, including empty spaces, in data, to analyse pre-treatment ALL datasets with known patient outcomes. We combine these fully unsupervised analyses with Machine Learning (ML) to identify significant shape characteristics and demonstrate that they accurately predict risk of relapse, particularly for patients previously classified as ‘low risk’. We independently confirm the predictive power of CD10, CD20, CD38, and CD45 as biomarkers for ALL diagnosis. Based on our analyses, we propose three increasingly detailed prognostic pipelines for analysing flow cytometry data from ALL patients depending on technical and technological availability: 1. Visual inspection of specific biological features in biparametric projections of the data; 2. Computation of quantitative topological descriptors of such projections; 3. A combined analysis, using TDA and ML, in the four-parameter space defined by CD10, CD20, CD38 and CD45. Our analyses readily extend to other haematological malignancies. Author summary: Acute lymphoblastic leukaemia (ALL) is a blood cancer which affects predominantly children and adolescents. Therapy typically fails in approximately 20 % of patients, who suffer from relapse. To determine disease status, clinicians assess cell types, their interactions, as well as deviations from normal behaviour. Flow cytometry (FC) is a method that quantifies the intensity of specific cell markers, giving rise to high-dimensional data. This routinely collected information is then reduced to obtain human-interpretable visualisation for prognosis. Topological Data Analysis (TDA) is a field of mathematics that studies shapes in data, considering isolated data islands and empty spaces between them. We showcase how to use TDA to extract shape characteristics in FC data of relapsing patients. We propose three pipelines, of increasing methodological complexity, to aid clinical decisions for risk stratification in ALL. In combination with Machine Learning, TDA enables high-accuracy predictions of relapse to be made at the time of diagnosis.
Open AccessThe shape of cancer relapse: Topological data analysis predicts recurrence in paediatric acute lymphoblastic leukaemia
Although children and adolescents with acute lymphoblastic leukaemia (ALL) have high survival rates, approximately 15-20% of patients relapse. Risk of relapse is routinely estimated at diagnosis by biological factors, including flow cytometry data. This high-dimensional data is typically manually assessed by projecting it onto a subset of biomarkers. Cell density and “empty spaces” in 2D projections of the data, i.e. regions devoid of cells, are then used for qualitative assessment. Here, we use topological data analysis (TDA), which quantifies shapes, including empty spaces, in data, to analyse pre-treatment ALL datasets with known patient outcomes. We combine these fully unsupervised analyses with Machine Learning (ML) to identify significant shape characteristics and demonstrate that they accurately predict risk of relapse, particularly for patients previously classified as ‘low risk’. We independently confirm the predictive power of CD10, CD20, CD38, and CD45 as biomarkers for ALL diagnosis. Based on our analyses, we propose three increasingly detailed prognostic pipelines for analysing flow cytometry data from ALL patients depending on technical and technological availability: 1. Visual inspection of specific biological features in biparametric projections of the data; 2. Computation of quantitative topological descriptors of such projections; 3. A combined analysis, using TDA and ML, in the four-parameter space defined by CD10, CD20, CD38 and CD45. Our analyses readily extend to other haematological malignancies. Author summary: Acute lymphoblastic leukaemia (ALL) is a blood cancer which affects predominantly children and adolescents. Therapy typically fails in approximately 20 % of patients, who suffer from relapse. To determine disease status, clinicians assess cell types, their interactions, as well as deviations from normal behaviour. Flow cytometry (FC) is a method that quantifies the intensity of specific cell markers, giving rise to high-dimensional data. This routinely collected information is then reduced to obtain human-interpretable visualisation for prognosis. Topological Data Analysis (TDA) is a field of mathematics that studies shapes in data, considering isolated data islands and empty spaces between them. We showcase how to use TDA to extract shape characteristics in FC data of relapsing patients. We propose three pipelines, of increasing methodological complexity, to aid clinical decisions for risk stratification in ALL. In combination with Machine Learning, TDA enables high-accuracy predictions of relapse to be made at the time of diagnosis.
- 1 August 2021
- Published by Elsevier in Journal of Theoretical Biology
- Vol. 522, 110685
Dynamical properties of feedback signalling in B lymphopoiesis: A mathematical modelling approach
- 1 August 2021
- Published by Elsevier in Journal of Theoretical Biology
- Vol. 522, 110685
Dynamical properties of feedback signalling in B lymphopoiesis: A mathematical modelling approach